Three of these bound to well-known autoantibody targets in SSc (Figure 2a): Anti-DNA topoisomerase 1 antibodies (anti-TOPO-1/Scl70; p = 0.016), anti-Tripartite motif containing 21 antibodies (anti-TRIM21/Ro52; p = 0.027), and Centromere Protein B (CENPB; p = 0.057), all showing a higher statistically significant prevalence in SSc compared to the controls. This evidence concerns the gene TRIM21 and systemic sclerosis.